Innovations to substantially increase output, decrease cost, and expand applications
SAN DIEGO--(BUSINESS WIRE)--
Illumina, Inc. (NASDAQ:ILMN) unveiled a development roadmap for its
Genome Analyzer system that charts a path to generate greater than 95
Gigabases of high quality data per run in 2009. This roadmap, which was
presented at a user-group meeting at this week’s Advances in Genome
Biology and Technology (AGBT) conference, outlined advances in
chemistry, algorithms, and hardware which will substantially improve
accuracy, read length, data density, and ease of use. These developments
chart a clear and demonstrable path for researchers to generate 25x
coverage of a human genome for less than $10,000 in 2009.
“The demonstrated pace of innovation on the Genome Analyzer has enabled
us and end-users to embark on ambitious, new whole-genome sequencing
projects that will have a major impact on human health, especially
cancer,” said David Bentley, Vice President and Chief Scientist of DNA
Sequencing at Illumina. “Currently we can generate greater than 25x
coverage of a human genome in three flow cells; a year ago, more than 40
flow cells were used to complete our first African genome. By year’s
end, we anticipate generating the same 25x coverage on a single flow
cell bringing the cost of acquiring a human genome sequence to below
The current configuration of the Genome Analyzer has the potential to
generate in excess of 15 Gigabases of high quality data per run. From
this baseline, the performance of the Genome Analyzer is expected to
increases greater than six-fold in 2009. The advances to achieve this
increase will be commercialized in several phases throughout the year
and include the following elements:
Chemistry advancements including new polymerases for sequencing and
cluster generation to enable faster run times and paired reads in
excess of 2x100 base pairs each. These advancements also improve
sequencing accuracy to greater than 98.5% for 2x100 paired end reads
and 99.9% for 2x50 paired end reads.
Hardware upgrades including improved flow cell holder and larger
reagent cooler provide an increase in output and walk-away automation
for reads of at least 100 cycles. These hardware components will
comprise the Genome AnalyzerIIx Upgrade Kit, which
current Genome Analyzer users can order immediately to increase the
output and enhance the automation of their system.
Algorithm improvements including a new approach to cluster detection
will increase output up to 80% on high density flow cells and improve
basecalling yielding greater accuracy and a larger proportion of
perfect reads per run.
Data density is increased by use of semi-ordered arrays of one micron
and subsequently sub-micron features. These ordered arrays, combined
with increases in read length, are expected to yield greater than 55
and 95 Gigabases per run respectively.
The combination of these advances will not only increase the output and
decrease the cost of sequencing on a Genome Analyzer, but also expand
the menu of applications that researchers can perform on the system.
Notably, de novo sequencing and assembly of complex genomes,
already possible with the Genome Analyzer, is considerably enhanced by
the capability to completely sequence DNA fragments of up to 250 base
pairs using the Illumina short-insert libraries and 150 base pair reads.
The ability to generate contiguous 250 base pair sequences allows
researchers to use a variety of existing long read assemblers for de
novo sequencing and metagenomics.
“With the largest installed base of next-generation platforms and over
200 peer-reviewed publications to date, the Illumina Genome Analyzer has
enabled a variety of scientists worldwide to conduct groundbreaking
research rapidly and cost effectively,” said Joel McComb, Senior Vice
President and General Manager of Illumina’s Life Sciences Business unit.
“With the planned system enhancements in 2009, we anticipate that the
Genome Analyzer will continue to provide a scalable and flexible
solution for a broad menu of applications, including large scale
whole-genome analysis, de novo sequencing, and metagenomics, and
accelerate the rate of discoveries leading to novel insights about human
health, biodiversity, and the environment.”
About the Genome Analyzer
Designed for facilities of all sizes, the Illumina Genome Analyzer has
been adopted across genome centers worldwide, as well as individual
research labs, core and service facilities, and biotechnology and
pharmaceutical companies. The Genome Analyzer offers the highest rate of
daily output and the simplest, most user-friendly workflow. The Genome
Analyzer supports the broadest set of applications, including those used
to profile and discover novel transcripts, to create high-resolution
genome-wide maps of DNA-protein binding sites and to sequence entire
human genomes to greater than 30x coverage.
For more information about the Genome Analyzer and to read what
customers are doing with Illumina's sequencing technology, please visit http://www.illumina.com/sequencing.
is a leading developer, manufacturer, and marketer of next-generation
life-science tools and integrated systems for the analysis of genetic
variation and biological function. Using our proprietary technologies,
we provide a comprehensive line of products and services that currently
serve the sequencing, genotyping, and gene expression markets, and we
expect to enter the market for molecular diagnostics. Our customers
include leading genomic research centers, pharmaceutical companies,
academic institutions, clinical research organizations, and
biotechnology companies. Our tools provide researchers around the world
with the performance, throughput, cost effectiveness, and flexibility
necessary to perform the billions of genetic tests needed to extract
valuable medical information from advances in genomics and proteomics.
We believe this information will enable researchers to correlate genetic
variation and biological function, which will enhance drug discovery and
clinical research, allow diseases to be detected earlier, and permit
better choices of drugs for individual patients.
"Safe Harbor" Statement under the Private Securities Litigation Reform
Act of 1995: this release may contain forward-looking statements that
involve risks and uncertainties. Among the important factors that could
cause actual results to differ materially from those in any
forward-looking statements are Illumina's ability (i) to develop and
commercialize further our BeadArray™, VeraCode®, and Solexa®
technologies and to deploy new sequencing, gene expression, and
genotyping products and applications for our technology platforms, (ii)
to manufacture robust instrumentation and reagents technology, together
with other factors detailed in our filings with the Securities and
Exchange Commission including our recent filings on Forms 10-K and 10-Q
or in information disclosed in public conference calls, the date and
time of which are released beforehand. We disclaim any intent or
obligation to update these forward-looking statements beyond the date of
Source: Illumina, Inc.
Sr. Director, Investor Relations